Phiogen

Developing next-generation bacteriophage therapeutics to treat and prevent drug-resistant and recurrent bacterial infections.

Website: https://phiogenpharma.com

Cover Block
Name Phiogen
Tagline Developing next-generation bacteriophage therapeutics to treat and prevent drug-resistant and recurrent bacterial infections.
Headquarters Houston, United States
Founded 2023
Stage Pre-Seed
Business Model Other
Industry Deeptech
Technology Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout
Funding Label Undisclosed

Links

What an Investor Needs First

Phiogen is a preclinical-stage biotech developing bacteriophage therapeutics that aim to both treat life-threatening drug-resistant infections and prevent their recurrence. The company was spun out of Baylor College of Medicine's TAILΦR Labs in June 2023, leveraging over a decade of clinical-grade phage discovery and development work. Its lead program, PHI-BI-01, is a novel therapeutic targeting extraintestinal pathogenic E. coli (ExPEC) bloodstream infections and is backed by a $1.1 million non-dilutive award from the global nonprofit CARB-X [Carb-X, 2025].

Publicly visible leadership includes Dr. Anthony W. Maresso, the Joseph Melnick Professor at Baylor and the scientific force behind the originating platform, alongside CEO Amanda (Curtis) Burkardt and COO Mayukh Das. Phiogen's funding path to date relies on non-dilutive capital. Over the next 12-18 months, key milestones include the progression of PHI-BI-01 through preclinical development, the potential announcement of a formal venture financing round, and any strategic partnerships that could validate its immunizing therapeutic approach. Data Accuracy: YELLOW -- Core product and spinout details are well-documented, but key financial and team specifics lack multiple independent public sources.

Taxonomy Snapshot

Axis Value
Stage Pre-Seed
Business Model Other (Therapeutic Developer)
Industry / Vertical Deeptech (Biotech / Life Sciences)
Technology Type Biotech / Life Sciences
Geography North America (Houston, United States)
Growth Profile Venture Scale
Founding Team Academic Spinout

Inside the Company

Phiogen is a preclinical biotechnology company that emerged directly from Baylor College of Medicine's TAILΦR Labs in June 2023 [EurekAlert!, 2023]. The company was founded to commercialize over a decade of academic phage biology research, establishing its headquarters within the Texas Medical Center in Houston, Texas. Its core mission is to develop next-generation bacteriophage therapeutics to address the escalating crisis of antimicrobial resistance.

In 2025, the company announced a $1.1 million award from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its lead therapeutic candidate, PHI-BI-01 [CARB-X, 2025]. The company has also been named one of the Top 10 most promising life science companies at the Texas Life Science Forum [gk.news]. Data Accuracy: YELLOW -- Company origin and location confirmed by academic press release; grant award and recognition confirmed by CARB-X and public relations sources.

Under the Hood

Phiogen’s core proposition is a platform for developing “immunizing therapeutics,” a dual-action approach that aims to treat an active, drug-resistant infection while simultaneously inducing a patient’s immune system to protect against recurrence. The company’s lead candidate, PHI-BI-01, is a novel, dual-action therapeutic designed to treat and prevent extraintestinal pathogenic E. coli (ExPEC) bloodstream infections [CARB-X, 2025].

The underlying technology is a high-throughput screening and development platform for bacteriophages. The platform is designed to discover rare phages with targeted capabilities, evolve “hyper-lytic” phages to overcome bacterial resistance, and test candidates in high-throughput biological models. This process is intended to move beyond bespoke, personalized phage therapy toward scalable, predictive product development. The platform builds directly on over a decade of foundational phage biology and clinical work from Baylor College of Medicine’s TAILΦR Labs [EurekAlert!, 2023]. Data Accuracy: GREEN -- Core product claims and platform description are consistently reported across multiple independent sources, including Baylor College of Medicine and CARB-X.

Market Research

Phiogen operates within the anti-microbial resistance (AMR) market, focusing specifically on high-unmet-need infections where existing antibiotics are failing. The company's initial wedge, targeting extraintestinal pathogenic E. coli (ExPEC) bloodstream infections, addresses a significant clinical burden. A 2022 report by the Global Antimicrobial Resistance Research and Development Hub estimated the global market for novel antibacterial agents could reach $1.6 billion by 2025 [Global AMR R&D Hub].

Metric Value
Global Novel Antibacterial Market (Analogous) $1.6B
CARB-X Award to Phiogen $1.1M
Data Accuracy: YELLOW -- Market sizing is based on an analogous third-party report; company-specific TAM/SAM is not publicly quantified. The CARB-X award amount is confirmed by the funder.

Competition and Substitutes

Phiogen operates in a competitive landscape defined by the urgent need for new antimicrobials. Its approach of combining immediate bacterial killing with long-term immune protection attempts to carve a distinct niche.

  • Traditional Pharmaceutical Incumbents. Large pharma companies have largely deprioritized novel antibiotic development, creating a market gap.
  • Specialty Biotech Challengers. This segment includes other phage therapy developers and companies pursuing alternative modalities like antimicrobial peptides, lysins, or antibody-based approaches.
  • Adjacent Substitutes. These include preventative measures like vaccines, microbiome modulators, and advanced diagnostics for antimicrobial stewardship.

Phiogen's defensible edge today appears to be its academic and clinical foundation. The company's technology is a direct commercial spin-out from Baylor College of Medicine's TAILΦR Labs, providing a starting library of clinically characterized phages and a discovery engine validated in a patient-care setting. The company's early validation through a $1.1 million CARB-X award for its lead program, PHI-BI-01, also signals external scientific credibility [CARB-X, 2025]. Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's stated market position; no direct competitor names are publicly confirmed in the provided sources.

Opportunity

Phiogen's opportunity is to build a new category of durable immunotherapies for bacterial infections, potentially capturing a multi-billion dollar segment of the global antimicrobial resistance (AMR) market. The company's platform builds directly on a clinical-grade phage discovery engine, TAILΦR Labs at Baylor College of Medicine, which has spent over a decade treating patients with personalized phage therapy. If successful, Phiogen would define a new therapeutic class for recurrent, drug-resistant infections where small molecules fail.

Scenario What happens Catalyst
Platform Licensing Phiogen's platform becomes the R&D engine for large pharma's AMR pipelines. A strategic R&D partnership or licensing deal.
Lead Asset Acquisition PHI-BI-01 demonstrates proof-of-concept and is acquired for late-stage development. Successful completion of a Phase 1/2a clinical trial.
Vertical Integration Phiogen develops a portfolio of immunizing therapeutics for chronic infections. Securing a traditional venture round.
Data Accuracy: YELLOW -- Core platform and opportunity claims are sourced from a detailed industry brief, but specific growth catalysts and comparable valuations are inferred from the company's positioning and market context.

Sources

Articles about Phiogen

Related companies

Topics

View on Startuply.vc